Eugene Durenard - 08 Jan 2022 Form 4 Insider Report for Co-Diagnostics, Inc. (CODX)

Reporting relationship: Director
Issuer ticker: CODX
Reported as of: 08 Jan 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Jan 2022, 16:05:13 UTC
Prior SEC filing: 22 Sep 2021
Next SEC filing: 12 Jul 2022
Source filing: View source filing
Reporting owner signature: /s/ Eugene Durenard

Key filing fact

Eugene Durenard filed Form 4 for Co-Diagnostics, Inc. (CODX) on 10 Jan 2022.

Key facts

This page summarizes Eugene Durenard's Form 4 filing for Co-Diagnostics, Inc. (CODX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 10 Jan 2022, 16:05.

Change

Previous filing in this sequence was filed on 22 Sep 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CODX transaction

Common Stock

Award

Transaction value: $0
Shares: +12,500
Change %
Price: $0.000000
Shares after: 12,500
Date: 08 Jan 2022
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CODX transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -12,500
Change %: -50%
Price: $0.000000
Shares after: 12,500
Date: 08 Jan 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 25,000
Exercise price: $0.000000
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Included in 37,500 restricted stock units awarded to the Reporting Person on January 8, 2021, pursuant to the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan, and vest in three equal installments every twelve months commencing on January 8, 2021.